Jasper Therapeutics (JSPR) Acquires Kira Pharmaceuticals, Accelerating Clinical Development of Vensobafusp Alfa
Strategic Combination of Two Biotechs to Target the Immuno-Oncology and Complement Disease Markets
Jasper Therapeutics (NASDAQ: JSPR), a Nasdaq-listed company, has merged with privately-held Kira Pharmaceuticals, a biotech focused on complement diseases, through a stock-for-stock transaction. This deal represents a strategic shift for Jasper, which had faced setbacks including clinical trial delays, to refocus its portfolio on the high unmet need areas of immune-mediated and complement diseases. The combined entity will be led by Jeet Mahal, CEO of Jasper, and aims to significantly strengthen its position in the development of therapies for rare diseases driven by complement system activation. With the increasing success of oral complement inhibitors like Novartis' Fabhalta, this merger is poised to be a new milestone in the next generation of therapeutic market competition.
Building a Clinical Roadmap Centered on Vensobafusp Alfa, a Key Complement Inhibitor
The core asset of the acquisition is vensobafusp alfa (development code KP-104), a dual-acting inhibitor that simultaneously blocks C5 protein and Factor B in the complement pathway. This compound demonstrates superior efficacy in inhibiting hemolysis compared to single-pathway inhibitors and targets paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G). Top-line data from a Phase 2 clinical trial in rare kidney diseases is expected in the fourth quarter of 2026, followed by discussions with the FDA regarding a Phase 3 trial. This has the potential to pose a significant challenge to existing therapies in the $4.2 billion PNH treatment market, such as AstraZeneca's Soliris.
Securing Financial Flexibility Through Asset Sales and the Mirador Deal
Concurrent with the merger, a strategic move was made to sell some of Kira's complement assets to Mirador Therapeutics, securing cash flow. Mirador acquired exclusive rights to anti-C5a monoclonal antibody KP-301 and small molecule C5aR antagonist KP-402 for a $12 million upfront payment. These assets target the ANCA-associated vasculitis (AAV) market, which is currently led by Amgen's Tavneos, and Mirador plans to initiate a Phase 1 clinical trial by the end of 2026. Through the swift divestiture of non-core assets, the combined Jasper-Kira entity has established a foundation to avoid redundant investments and concentrate capital on its key pipeline assets, vensobafusp alfa and anti-KIT antibody briquilimab.
Securing $132 Million in Funding and Extending Cash Runway to 2028
In addition, the merger was accompanied by a $132 million private investment (PIPE), resolving the combined entity's clinical financial risks. This PIPE investment, led by Affinity Asset and Ikarian Capital, provides a secure research and development funding runway through the second half of 2028. Upon completion of the transaction, Kira shareholders will own 49.86%, PIPE investors will own 43.46%, and Jasper shareholders will own 6.68% of the combined entity. This represents a successful financial maneuver, allowing the private company Kira to leverage Jasper's public listing to gain access to the Nasdaq market.
The newly formed Jasper Therapeutics (NASDAQ: JSPR) has secured $132 million in new capital through this merger, proactively extending its clinical research funding runway to the second half of 2028. In the short term, the top-line data from the Phase 2 clinical trial of vensobafusp alfa, a dual C5 and Factor B inhibitor, in rare kidney diseases, expected in the fourth quarter of 2026, will be a key indicator of the company's medium- to long-term growth prospects. This will be a pivotal moment in the $4.2 billion PNH treatment market, currently dominated by oral drugs like Novartis' Fabhalta, as the company leverages its unique dual complement inhibition mechanism to diversify the competitive landscape. Furthermore, Mirador's acquisition of anti-C5a antibody KP-301 and its planned Phase 2 clinical trial in ANCA-associated vasculitis (expected in the first half of 2027), along with Jasper's plans to resume clinical trials for anti-KIT antibody briquilimab in severe combined immunodeficiency (SCID), offer promising portfolio opportunities for researchers and investors.